{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:10:21Z","timestamp":1789755021448,"version":"4.0.1"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII-222823"],"award-info":[{"award-number":["CRSII-222823"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["SNSF 320030-232217"],"award-info":[{"award-number":["SNSF 320030-232217"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["SNSF-31030_204124"],"award-info":[{"award-number":["SNSF-31030_204124"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017035","name":"Fondation ISREC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031252","name":"Carigest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","award":["KFS-6045-02-2024"],"award-info":[{"award-number":["KFS-6045-02-2024"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-CoG EVOLVE-725051"],"award-info":[{"award-number":["ERC-CoG EVOLVE-725051"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.it.2026.08.013","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:19:23Z","timestamp":1789561163000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dendritic cells as programmable platforms for cancer immunotherapy"],"prefix":"10.1016","author":[{"given":"Yuchen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Marcandalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bayerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael J.","family":"Pittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-5459","authenticated-orcid":false,"given":"Michele","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2026.08.013_bb0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0015","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41419-025-08180-0","article-title":"The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy","volume":"16","author":"Xie","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.it.2026.08.013_bb0020","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","article-title":"Dendritic cells as shepherds of T cell immunity in cancer","volume":"56","author":"Pittet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2096363","article-title":"Trial watch: dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2026.08.013_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: anticancer vaccination with dendritic cells","volume":"13","author":"Borges","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2026.08.013_bb0045","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","article-title":"Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells","volume":"2","author":"Hsu","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0065","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0075","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0080","first-page":"5091","article-title":"Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients","volume":"9","author":"de Vries","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.08.013_bb0085","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.bjc.6600316","article-title":"Generation of dendritic cell-based vaccines for cancer therapy","volume":"86","author":"Reinhard","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","article-title":"Antitumour dendritic cell vaccination in a priming and boosting approach","volume":"19","author":"Harari","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.08.013_bb0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41577-020-00413-x","article-title":"Genetic models of human and mouse dendritic cell development and function","volume":"21","author":"Anderson","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0110","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/eji.202149632","article-title":"Human dendritic cell subsets: an updated view of their ontogeny and functional specialization","volume":"52","author":"Segura","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0115","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.it.2026.08.013_bb0125","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200264","article-title":"Tumor-infiltrating dendritic cell states are conserved across solid human cancers","volume":"218","author":"Gerhard","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0130","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/cells12172147","article-title":"Dendritic cell vaccines: a shift from conventional approach to new generations","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.it.2026.08.013_bb0135","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241199","article-title":"Leveraging cDC1 biology and function for enhanced immunotherapy","volume":"223","author":"Ward","year":"2026","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-immunol-041015-055254","article-title":"The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules","volume":"35","author":"Cruz","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nmeth.4579","article-title":"EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens","volume":"15","author":"Squadrito","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.it.2026.08.013_bb0150","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216523","article-title":"Dendritic cell cross-dressing and tumor immunity","volume":"14","author":"Martinez-Usatorre","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0155","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) Dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0165","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","article-title":"A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity","volume":"41","author":"Meiser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101711","article-title":"The evolving biology of cross-presentation","volume":"66","author":"Ohara","year":"2023","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0175","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1073\/pnas.1203468109","article-title":"Cross-dressed CD8\u03b1+\/CD103+ dendritic cells prime CD8+ T cells following vaccination","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci.U S A"},{"key":"10.1016\/j.it.2026.08.013_bb0180","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0185","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0190","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","article-title":"CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment","volume":"184","author":"Di Pilato","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0195","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.immuni.2025.11.020","article-title":"Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity","volume":"59","author":"Zitti","year":"2026","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0210","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.08.013_bb0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1189\/jlb.0812397","article-title":"Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive\/tolerogenic cells: insight into the molecular mechanisms","volume":"93","author":"Demoulin","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.it.2026.08.013_bb0220","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-026-73721-w","article-title":"Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells","volume":"17","author":"Caro","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0225","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0230","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","article-title":"Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166180","article-title":"Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models","volume":"14","author":"Clappaert","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0240","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","article-title":"Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab","volume":"30","author":"Alban","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","article-title":"Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development","volume":"26","author":"Huber","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0250","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0255","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-023-01430-8","article-title":"Novel strategies for cancer immunotherapy: counter-immunoediting therapy","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0265","first-page":"240","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.it.2026.08.013_bb0270","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0357","article-title":"Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms","volume":"30","author":"Werner","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0275","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0280","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0290","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","article-title":"Dendritic cell maturation in cancer","volume":"25","author":"Moon","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0300","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2013 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0305","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","article-title":"Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy","volume":"632","author":"Sultan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0310","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.it.2026.08.013_bb0315","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0320","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.08.013_bb0325","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","article-title":"Suppression of antigen presentation by IL-10","volume":"34","author":"Mittal","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0335","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","article-title":"Tumor-derived lactic acid modulates dendritic cell activation and antigen expression","volume":"107","author":"Gottfried","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.08.013_bb0340","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0345","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0350","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"Melssen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","article-title":"Mechanisms driving the immunoregulatory function of cancer cells","volume":"23","author":"van Weverwijk","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0365","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0370","first-page":"827","article-title":"Milestones in tumor vascularization and its therapeutic targeting","volume":"5","author":"De Palma","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.it.2026.08.013_bb0375","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.ccell.2024.11.002","article-title":"Myeloid effector cells in cancer","volume":"42","author":"Schol","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578349","article-title":"Leveraging endogenous dendritic cells to enhance the therapeutic efficacy of adoptive T-cell therapy and checkpoint blockade","volume":"11","author":"H\u00fcbbe","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0385","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.it.2026.08.013_bb0390","article-title":"Dendritic cell immunotherapy advances for solid tumors: vaccination and modulation","volume":"6","author":"Clayton","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.it.2026.08.013_bb0395","first-page":"1204","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.it.2026.08.013_bb0400","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0405","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0410","first-page":"287","article-title":"Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting","volume":"3","author":"Salomon","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.it.2026.08.013_bb0415","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0420","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/bs.ircmb.2023.02.002","article-title":"The role of dendritic cells in radiation-induced immune responses","volume":"378","author":"Preet Kaur","year":"2023","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.it.2026.08.013_bb0425","first-page":"1104","article-title":"Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases","volume":"7","author":"Navarre","year":"2026","journal-title":"Nat. Can."},{"key":"10.1016\/j.it.2026.08.013_bb0430","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1667\/RR13495.1","article-title":"Radiation as immunomodulator: implications for dendritic cell-based immunotherapy","volume":"182","author":"Roses","year":"2014","journal-title":"Radiat. Res."},{"key":"10.1016\/j.it.2026.08.013_bb0435","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic dna sensing promotes radiation-induced type I Interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0445","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1038\/s41467-025-60927-7","article-title":"Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0450","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0455","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41565-023-01553-6","article-title":"Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.it.2026.08.013_bb0460","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.smim.2011.01.001","article-title":"Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines","volume":"23","author":"Tacken","year":"2011","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0465","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri2173","article-title":"Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting","volume":"7","author":"Tacken","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0470","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.20032220","article-title":"In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination","volume":"199","author":"Bonifaz","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0475","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2518080123","article-title":"Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity","volume":"123","author":"Fu","year":"2026","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2026.08.013_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114799","article-title":"Lipid-based delivery systems for dendritic cell targeting: formulation strategies and cancer applications","volume":"393","author":"Fredericq","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.it.2026.08.013_bb0485","article-title":"Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy","volume":"11","author":"Zhang","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.it.2026.08.013_bb0490","article-title":"Recent advances in lipid nanoparticles for cancer vaccine delivery: challenges and future perspectives","volume":"11","author":"Hasan","year":"2026","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.it.2026.08.013_bb0495","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0500","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0505","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-026-70876-4","article-title":"Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0510","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41551-021-00800-2","article-title":"Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells","volume":"5","author":"Liu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.it.2026.08.013_bb0515","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0520","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0525","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd3220","article-title":"Sipuleucel-T","volume":"9","author":"Higano","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.08.013_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012367","article-title":"Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer","volume":"5","author":"Frank","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2026.08.013_bb0535","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0540","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0545","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0550","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-019-02466-x","article-title":"Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial","volume":"69","author":"Boudewijns","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.08.013_bb0555","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006665","article-title":"Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III\/IV melanoma: a prespecified 36-month analysis","volume":"11","author":"Carpenter","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0560","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","article-title":"A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of stage III\/IV melanoma: a primary analysis","volume":"28","author":"Vreeland","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0565","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-022-03272-8","article-title":"Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial","volume":"72","author":"Adams","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.08.013_bb0570","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40425-019-0552-x","article-title":"Multiple antigen-engineered DC vaccines with or without IFN\u03b1 to promote antitumor immunity in melanoma","volume":"7","author":"Butterfield","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0575","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1038\/s41467-023-42881-4","article-title":"Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients","volume":"14","author":"Adamik","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0580","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2024-200876","article-title":"Randomized phase II trial of dendritic cell\/AML fusion cell vaccination compared to standard of care therapy in AML CR1","volume":"144","author":"Pophali","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.08.013_bb0585","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1200\/JCO.2019.37.15_suppl.e13526","article-title":"Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma","volume":"37","author":"Peters","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0590","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1172\/JCI67544","article-title":"Melanoma immunotherapy using mature DCs expressing the constitutive proteasome","volume":"123","author":"Dannull","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2026.08.013_bb0595","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12967-014-0338-3","article-title":"Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer","volume":"12","author":"Frank","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0600","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1207842","article-title":"mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma","volume":"5","author":"Borch","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2026.08.013_bb0605","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105844","article-title":"Innovative therapeutic cancer vaccine PDC*lung01 with or without anti-PD-1: an open-label, dose-escalation phase I\/II study in non-small cell lung cancer","volume":"10","author":"Vansteenkiste","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.it.2026.08.013_bb0615","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1738812","article-title":"An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial","volume":"9","author":"Charles","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2026.08.013_bb0620","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0625","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0630","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011144","article-title":"CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells","volume":"5","author":"Yewdall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2026.08.013_bb0640","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135143","article-title":"IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction","volume":"5","author":"Ashour","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.it.2026.08.013_bb0645","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","article-title":"cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1","volume":"10","author":"Ferris","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.it.2026.08.013_bb0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0655","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1038\/s41467-025-64172-w","article-title":"Dendritic cell progenitors engineered to express extracellular-vesicle\u2013internalizing receptors enhance cancer immunotherapy in mouse models","volume":"16","author":"Ghasemi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0660","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fmicb.2014.00006","article-title":"Blood dendritic cells: \u201ccanary in the coal mine\u201d to predict chronic inflammatory disease?","volume":"5","author":"Miles","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.it.2026.08.013_bb0665","doi-asserted-by":"crossref","first-page":"326","DOI":"10.15283\/ijsc19157","article-title":"Hematopoietic stem cells culture, expansion and differentiation: an insight into variable and available media","volume":"13","author":"Yadav","year":"2020","journal-title":"Int. J. Stem Cells"},{"key":"10.1016\/j.it.2026.08.013_bb0670","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.celrep.2018.07.033","article-title":"Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity","volume":"24","author":"Balan","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2026.08.013_bb0675","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.4049\/jimmunol.1401243","article-title":"Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells","volume":"193","author":"Balan","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0680","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha","volume":"179","author":"Sallusto","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0685","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood-2013-12-545772","article-title":"Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow","volume":"124","author":"Mayer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.08.013_bb0690","article-title":"FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis","volume":"4","author":"R\u00e9gnier","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0695","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","article-title":"GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells","volume":"42","author":"Helft","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0700","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/s41467-020-15937-y","article-title":"Engineered niches support the development of human dendritic cells in humanized mice","volume":"11","author":"Anselmi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0705","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2026.2695692","article-title":"Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity","volume":"15","author":"Cuenca-Escalona","year":"2026","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2026.08.013_bb0710","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae059","article-title":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas","volume":"8","author":"Di","year":"2024","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.it.2026.08.013_bb0715","doi-asserted-by":"crossref","first-page":"21757","DOI":"10.1038\/srep21757","article-title":"Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application","volume":"6","author":"Torikai","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2026.08.013_bb0720","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.humimm.2022.03.002","article-title":"A clinician\u2019s guide to HLA matching in allogeneic hematopoietic stem cell transplant","volume":"83","author":"Mangum","year":"2022","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0725","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-024-01022-8","article-title":"Engineering immune-evasive allogeneic cellular immunotherapies","volume":"24","author":"Martin","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0730","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0735","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41232-020-00132-9","article-title":"Current status and future perspectives of HLA-edited induced pluripotent stem cells","volume":"40","author":"Koga","year":"2020","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.it.2026.08.013_bb0740","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent stem cell-based cell therapy-promise and challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0745","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.stem.2024.12.005","article-title":"Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update","volume":"32","author":"Kirkeby","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.it.2026.08.013_bb0750","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/eji.202149550","article-title":"Dendritic cells generated from induced pluripotent stem cells and by direct reprogramming of somatic cells","volume":"52","author":"Flosdorf","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0755","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.3095","article-title":"Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy","volume":"38","author":"Horton","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.it.2026.08.013_bb0760","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf045","article-title":"Efficient generation of human dendritic cells from induced pluripotent stem cell by introducing a feeder-free expansion step for hematopoietic progenitors","volume":"117","author":"Elahi","year":"2025","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.it.2026.08.013_bb0765","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41467-022-30557-4","article-title":"Robust temporal map of human in vitro myelopoiesis using single-cell genomics","volume":"13","author":"Alsinet","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0770","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.667304","article-title":"Human DC3 antigen presenting dendritic cells from induced pluripotent stem cells","volume":"9","author":"Satoh","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.it.2026.08.013_bb0775","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3389\/fimmu.2017.01935","article-title":"Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset","volume":"8","author":"Sachamitr","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0780","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.08.013_bb0785","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s12276-024-01353-5","article-title":"Cytokine-overexpressing dendritic cells for cancer immunotherapy","volume":"56","author":"Han","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0790","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.it.2026.08.013_bb0795","article-title":"IL-12 and GM-CSF engineered dendritic cells enhance the enrichment and selection of tumor-reactive T cells for cancer immunotherapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0800","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41467-023-40886-7","article-title":"Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.08.013_bb0805","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq4060","article-title":"Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors","volume":"17","author":"Mohammadzadeh","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0810","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013040","article-title":"Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models","volume":"13","author":"Minnee","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.08.013_bb0815","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/85438","article-title":"Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming","volume":"7","author":"Wolfers","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0820","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41598-023-27604-5","article-title":"CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality","volume":"13","author":"Ukrainskaya","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2026.08.013_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108960","article-title":"Disentangling the complexity of tumor-derived extracellular vesicles","volume":"35","author":"Beltraminelli","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2026.08.013_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101710","article-title":"MHC-dressing on dendritic cells: boosting anti-tumor immunity via unconventional tumor antigen presentation","volume":"66","author":"Chatterjee","year":"2023","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0835","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-026-10353-6","article-title":"mRNA vaccines engage unconventional pathways in CD8+ T cell priming","volume":"654","author":"Jo","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.08.013_bb0840","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.08.013_bb0845","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/mt.2012.11","article-title":"Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients","volume":"20","author":"Van Nuffel","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2026.08.013_bb0850","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","article-title":"Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer","volume":"9","author":"Versteven","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0855","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.08.013_bb0860","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2026.08.013_bb0865","doi-asserted-by":"crossref","first-page":"18192","DOI":"10.18632\/oncotarget.4145","article-title":"Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer","volume":"6","author":"Podrazil","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2026.08.013_bb0870","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.08.013_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2026.06.003","article-title":"Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations","author":"Gomis","year":"2026","journal-title":"Trends Immunol."},{"key":"10.1016\/j.it.2026.08.013_bb0880","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3311","article-title":"T cell-induced CSF1 promotes melanoma resistance to PD1 blockade","volume":"10","author":"Neubert","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112975","article-title":"Trajectories of macrophage ontogeny and reprogramming in cancer","volume":"28","author":"Duval","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.it.2026.08.013_bb0890","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.08.013_bb0895","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1073\/pnas.1902145116","article-title":"Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy","volume":"117","author":"Kashyap","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:36:40Z","timestamp":1789753000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490626002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":179,"alternative-id":["S1471490626002292"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2026.08.013","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendritic cells as programmable platforms for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2026.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}